Background and Aims: Success in delivering value-based healthcare involves measuring outcomes that matter most to patients. Our aim was to develop a minimum Standard Set of patient-centred outcome measures for inflammatory bowel disease [IBD] 
Introduction
A paradigm change is happening in healthcare. Many healthcare organizations are embracing value-based healthcare, [1] [2] [3] [4] an approach that aims to achieve the best possible health outcomes for the lowest cost. 5, 6 According to the framework presented by Porter et al., 7 the key to determining "value" is measuring outcomes that matter most to patients. When providers are asked to report outcomes, performance improves, 1 even when those outcomes are not patient-defined. Outcome measurement [in contrast to more familiar measures of the care-delivery process 5, 6 ] has the potential to direct resources towards strategies with the highest value, which is particularly relevant for chronic diseases that are major drivers of healthcare costs. 8 For complex conditions such as inflammatory bowel disease [IBD] , the potential gain from a value-driven healthcare strategy could be even greater than conditions with defined interventions, such as cataract surgery. 9 Crohn's disease [CD] and ulcerative colitis [UC] , collectively known as IBD, disproportionately affect young adults in their educationally and economically productive years, leading to reduced quality of life, social functioning and productivity, [10] [11] [12] [13] often requiring lifelong drug treatment or major surgery. 14, 15 This accounts for high costs to the healthcare system and society, 10, 16, 17 with annual direct healthcare costs in Europe alone estimated at 4.6-5.6 billion Euros, and a global rise in burden, particularly in East Asia. 12, [18] [19] [20] Despite the potential impact on the individual, no patient-reported outcome measures [PROMs] are used in routine practice, so patient-reported outcomes [PROs] , other than disease-related symptoms, are rarely captured. Furthermore, there remains widespread variation in clinical practice and quality of care provided to patients with IBD. [21] [22] [23] With the exception of collaborations such as the ImproveCareNow network, [24] [25] [26] current IBD registries track different outcomes or similar outcomes with different definitions, making meaningful comparisons between populations difficult. 27 Similarly, no 'core outcome sets' are currently available for IBD clinical trials to date, limiting the ability for direct comparison or combining of results. 28 To align outcome measurement in IBD as a step towards valuedriven care, the Oxford Academic Health Science Network collaborated with International Consortium for Health Outcomes Measurement [ICHOM] 21 Standard Sets of outcomes for different medical conditions that are being implemented in practice. [29] [30] [31] [32] [33] [34] [35] The advantage of this collective effort is that all use standardized methodology; consequently, each condition becomes part of a wider whole for introducing outcome measurement into routine practice, facilitating implementation when different disease areas can learn from others.
Our goal was to develop a minimum Standard Set of patient-centred outcomes for IBD to provide a common language for outcomes that can be tracked systematically.
Materials and Methods

Context and overview
The Standard Set for patients with IBD [age ≥16 years] aims to provide a template with meaningful, comparable and easy-to-interpret measures that can be implemented in any healthcare setting to track and compare outcomes. It represents a 'minimum' standard to cover the cycle of care for both CD and UC and tracks health status [ Figure 1 5 ], while not precluding collection of additional measures. Selection principles for outcomes were: 36, 37 In the selection of the PROM tool, we aimed to capture health status and impact on quality of life beyond specific diseaserelated symptoms, using a validated instrument applicable to both CD and UC. Time points for data collection were determined by considering these principles and the burden of data capture on the patient or provider.
Case Any items where consensus was not reached but ranked 7-9 by at least 50-70% of respondents were further discussed, followed by a second survey. Items ranked 7-9 by <50% of respondents were excluded from further surveys. Similarly, any newly introduced items, change in definition or timing of collection were subject to further surveys to reach consensus. All voted items were reviewed at the subsequent teleconference, whether voted in or out as per pre-defined consensus definition, to provide an additional opportunity for any of the Working Group members to challenge or confirm their inclusion. A "patient focus group", including six IBD patients and two "1:1 patient interviews" were conducted 39 by CR after the Working Group launch, to obtain patients' perspectives on outcomes that matter most to them, using a structured interview and open-ended questions. Participants, nominated by CCUK and Crohn's & Colitis Australia, discussed which outcomes were of greatest importance to them. The focus groups represented a mix of patients with CD or UC who had received a variety of surgical and/or medical treatments with different healthcare utilization experiences. Additional 1:1 interviews were undertaken for one man and one pregnant woman. Representatives of patient associations and other Working Group members shared their experience with other patient focus groups 22, [40] [41] [42] during teleconferences to confirm that the most important patient-reported outcome domains and patient concerns were represented in the Standard Set.
The resulting Standard Set was approved unanimously by the Working Group before being subject to "patient validation surveys" and a period of "open review" by interested clinicians before finalization. The patient validation surveys involved circulation of the Standard Set to a geographically and culturally diverse group of patients, with the aid of multiple patient organizations, including CCUK and Crohn's & Colitis Australia, as well as local patient groups invited by Working Group members from Brazil, India and China [PK, RB, ZhR]. The survey was translated into French, Hindi, Brazilian Portuguese, and simplified Chinese. It was completed by 318 patients representing a diverse age group and diverse geographical locations, with 83% indicating that they felt that the current Standard Set captured the most important outcomes that matter or have mattered to them [see Supplementary Material 2, which can be found at Journal of Crohn's and Colitis Online]. A web-based draft version of the Standard Set was made available to interested clinicians, ICHOM website registrants and other stakeholders for comment on the Standard Set before finalization.
Results
Scope: Patients with Inflammatory Bowel Disease
The agreed focus [75%, n = 16 /20] 
Systematic Review of IBD-related Outcomes and Measures
Using a defined hierarchy, 5 outcomes and metrics were selected from 565 papers and abstracts for the Working Group, which was further informed by registry databases and input from patient focus groups. In the four domains, 239 preliminary outcome measures were identified, from which 14 measures and their instruments were selected [see Supplementary Material 3 Figure 2 ]. Although death attributable to IBD is infrequent, it is of overriding relevance to patients, highlighted by patient focus groups. Capturing overall survival allows the ultimate impact of care to be assessed. Recognizing the limitations of death registries and reporting in many countries, the Working Group voted [82%, n = 14/17] to include both "overall and IBD-specific survival". The Working Group recommends tracking survival each year.
Control of "disease activity and remission" is one of the major goals of treatment. Defining remission, however, is not straightforward, and no agreed tool currently exists to capture disease activity, which in itself can be defined in many ways. There is often discrepancy between the patient's symptoms and their state of biological remission, so the Working Group considered these separately. The consensus [100%, n = 17/17] was to use the Manitoba IBD index [MIBDI] 47 [ Table 2 ] for both UC and CD at baseline and 6-monthly intervals. The MIBDI is a single-item, patient-defined disease activity measure reported on a 6-point Likert scale allowing a 6-month recall period. It has been validated against the Harvey-Bradshaw Index, the Powell-Tuck Index, and the Inflammatory Bowel Disease Questionnaire [IBDQ] . 48 The Working Group decided [88%, n = 16/18; 94%, n = 17/18] that the clinician should separately report clinical remission and biological remission, and document how biological remission was determined [biochemical, endoscopic, imaging].
"Colorectal cancer", although infrequently complicating IBD, 49 was important to patient focus groups. The Working Group agreed [94%, n = 16/17], since treatment may alter this outcome. Annual tracking of a definitive diagnosis was recommended, and for affected patients, reporting whether colorectal dysplasia had previously been diagnosed, and whether they had been participating in colorectal cancer surveillance. Surveillance details were considered to be beyond the scope of minimum standards. "Anaemia", defined by the World Health Organization [WHO], 50 was recommended [71%, n = 12/17] as an independent marker of disease activity and potentially modifiable outcome, tracked at baseline and at 6-monthly intervals.
Healthcare Utilization
Two measures were selected [ Figure 2 ]. Unplanned admissions or Emergency Department visits concern patients with IBD, since they can imply suboptimal disease control, non-specialist care, or increased use of ionizing radiation [CT scans]. 22 To achieve a practical measure, the Working Group recommended [71%, n = 12/17] recording "the total number of emergency room visits every 12 months" and "all IBD-related admissions requiring at least an overnight stay", defined as planned or unplanned, and recording the total length of stay in days over a 12-month period.
Disutility of Care
Two measures were selected [ Figure 2 ]. "Complications resulting from IBD-related treatment" are a central concern for patients that informs their choices about management. Attribution to disease or therapy is contentious, and determining severity is difficult. The Working Group recommended [76%, n = 14/18] documenting a complication that occurred during or within 3 months of any treatment [medical, endoscopic, radiological, or surgical], separately recording the outcome [further intervention, unplanned admission, or prolonged hospitalization].
Steroid dependency is a cause of morbidity in IBD, is a concern to patients and may reflect quality of care. 51, 52 The Working Group recommended [82%, n = 14/17] documenting any systemic "steroid use" within the previous 12 months and whether the duration exceeded 3 months. 42 applied every 6 months. All IBDspecific PROMs were examined by specialists within the Working Group [RF, WvD] for their conceptual and measurement designs, domain coverage and psychometric properties using ISOQOL criteria [ Table 3 ]. 36 Although the best established PROM in IBD is the Inflammatory Bowel Disease Questionnaire [IBDQ], 48 it has failed to embed itself in clinical practice because of its length and need for a licence. The IBD-Control questionnaire 42 captures disease control from the patient's perspective using generic language and measuring themes with which all patients with IBD can identify. It can be administered in less than a minute and has shown strong validity against the EQ-5D, 53 fistula [none, perianal, rectovaginal, enterocutaneous, or other] was added, to be completed at baseline and at 6-monthly intervals.
Case-mix Variables for Risk Adjustment
The Working Group defined a minimum set of patients' baseline characteristics [ Table 5 ] to enable comparisons of outcomes between centres, regions or countries to be placed in context. Selection had to be practical to capture in routine care, balancing the burden with the need for accurate comparisons. Demographics and baseline clinical factors will be patient-reported, while baseline condition and treatment factors will be clinicianreported at baseline, and tracked annually as appropriate for smoking status, disease location/behaviour and treatment.
Discussion
A "minimum" set of standardized outcome measures represents a common language that can be used across healthcare jurisdictions as a step towards value-driven care in IBD. Value-driven care relies on reporting and systematic tracking of patient-centred outcomes, allowing providers to compare meaningful outcomes for patients and to adopt strategies that achieve the best "value" for participating stakeholders. This work represents a first step. The performance characteristics of the measures need evaluating in real-world practice. If adopted and implemented, such an approach has the potential to reduce variations in practice and improve standards of care on a global scale. Existing studies show wide variations in the quality and delivery of care in IBD and suggest significant potential for improvement. National audit in the UK in 2006 led to the development of a set of IBD Standards that defined key performance indicators and recommendations for quality, patient-centred care. 23 In the USA, a collaborative of paediatric IBD centres formed the ImproveCareNow network to develop an outcomes registry using a shared, prospective database between nearly 50 centres. Over Table 2 . The Manitoba IBD Index. 47 In the last 6 months, my disease has been 0 = Constantly active, giving me symptoms every day 1 = Often active, giving me symptoms most days 2 = Sometimes active, giving me symptoms on some days [for instance 1-2 days/week] 3 = Occasionally active, giving me symptoms 1-2 days/month 4 = Rarely active, giving me symptoms on a few days in the past 6 months 5 = I was well in the past 6 months: what I consider a remission or absence of symptoms the years, remission rates within the participating centres have increased from 55% to 75%, using the physician's global assessment. 24 This highlights what can be achieved when the provision of care is driven by outcomes.
The Standard Set presented here is the first coordinated international, multidisciplinary effort to reach a precisely defined core set of outcomes for all adult patients with IBD. The development process has followed reporting guidelines for core outcome sets. 58 This is an advantage, because IBD becomes just one of many [21 diseases as of 2017, www.ichom.org] diseases subject to the same process. The final Standard Set [ Figure 2 ] tracks 14 outcome measures that encompass the full cycle of care for both CD and UC, as well as health status beyond completion of care. The selection process was guided by careful consideration of the hierarchy of outcome measures and pre-specified domains. Each of the selected outcome measures was subject to voting on definition, response options and data source in a formal consensus process. Practicality in terms of burden on the patient and/or the provider, and feasibility in a broad range of healthcare settings were additional considerations.
Importantly, the Standard Set emphasizes outcomes that matter most to patients. The US Food and Drugs Administration has advocated routine inclusion of PROs as co-primary endpoints in clinical trials. 59 Although improving quality of life is a common secondary endpoint in clinical trials, it has been the primary endpoint in only one trial in IBD 60 and is rarely captured in routine practice. While the IBDQ has been widely used in trials, it has failed to embed itself in routine practice because of its length, and pragmatic reasons of cost and administrative burden. A shorter version, 61 and other more recent variations of the IBDQ such as the UK version of the IBDQ 54 and Crohn's and Ulcerative Colitis Questionnaire 62 have similarly failed to gain popularity. The IBD-Control Questionnaire, 42 unanimously recommended by the Working Group, is a PROM tool developed with the primary aim of supporting patient-centred care in practice. It captures the patient's perspective on disease control using a simple set of generic items applicable to all patients with IBD. It is freely available without a licence and takes less than 60 s to complete, which gives it great potential in routine practice. Strong psychometric properties have led to its selection for the UK IBD registry, although it is yet to be validated in other languages apart from Spanish. The Standard Set of outcomes defined here are designed for clinical practice and would only be adaptable to clinical trials once performance characteristics are defined by prospective measurement. Parallel efforts to define PROMs in IBD have been driven by the CCFA within the USA, and the 10 most highly rated process and outcome measures were published in 2013. 22 The current Working Group took advantage of this work by including key patient, association and clinical specialist representatives involved in the CCFA process. Similarly, the National Institutes of Health Patient-Reported Outcomes Measurement Information System metrics were developed for gastrointestinal symptoms in 2014. 63 The development process and selected measures of both these initiatives reassuringly have much in common with ICHOM, but challenges remain with standardization of these measures. Nevertheless, the Standard Set has limitations. The patient numbers involved in focus groups and face-to-face interviews were few: however, unlike evidence-based science, the methodology of qualitative research and quality improvement depends not on numbers but on the extent to which concepts reflect the opinions of representative groups. There is no standard for determining an adequate group size, 64 and work in other fields has considered groups of 5-10 patients to be optimal. 39, 65 Symptom domains of importance and concerns identified by our focus groups reflected those of earlier work by patient associations and others. 23, 40, 41, [66] [67] [68] Patient representatives on the Working Group [MD, JM, HT, AW] present for the discussions and final decisions represented large patient organizations [CCFA, CCUK, and AFA]. More patients, groups and a wider validation survey might have been involved, but a balance had to be struck between resources and delivery within a 12 month time frame.
Despite the Working Group's best efforts to develop consensus definitions that were unambiguous, cultural characteristics and infrastructural differences will inevitably influence local data. For some measures, this meant that a broad definition had to be adopted. For example, although readmission and unexpected admission were identified as important outcomes for the domain Healthcare Utilization, the Working Group recognized the variation in thresholds for admission that exists between healthcare providers. It therefore chose to measure total length of stay and separately to track ED visits. The Standard Set also includes outcome measures that rely on pre-existing registry or administrative data. This is relevant for the Survival domain. Inaccurate or inconsistent information with respect to cause of death is well recognized. However, death is a central concern to patients, so could not reasonably be excluded as an outcome. The Working Group chose to include "unknown" as a response option for cause of death. Furthermore, not all outcome measures had practical definitions or validated tools available. This was the case for nutrition. Existing tools such as the Malnutrition Universal Screening Tool 69 act as a screening tool for referral [process Participation in a colorectal cancer surveillance programme measure] rather than monitoring. Tools requiring anthropometrics or incorporating biochemical measures were considered impractical. The Working Group chose to measure height and weight at baseline for BMI calculation and then change in weight as a surrogate marker of nutritional status and an outcome of care, because this is a universally available, objective measure in low-income countries where access to more costly assessments may be difficult. We used a modified two-round Delphi process to reach consensus on each of the selected outcome measures, and case-mix variables including "how" and "when" these should be captured. The level of consensus deemed necessary in the Delphi process remains ambiguous in the literature, and there are no agreed norms for size of consensus, with practice varying from basic majority to more stringent proportions. The level of agreement used in our work was pragmatic, based on other successfully conducted international consensus processes for outcomes, including those used by ICHOM in other published Standard Sets. Notably, the Core Outcome Measures in Effectiveness Trials initiative used this cut-off. 70 The minimum denominator for all votes was 17, representing 77-81% of the Working Group members [excluding the Project Team]. It should be noted that while numbers formally participating in any given vote varied, all Working Group members were subsequently prompted for feedback and had the opportunity to confirm or challenge the results. The final Standard Set was approved unanimously by the Working Group.
This international, multidisciplinary IBD Working Group has developed a minimum set of patient-centred outcomes, tools and PROMs for collection in patients with IBD. Data collection needs to be piloted and a standardized collection platform developed before data quality and outcomes can be compared in different settings. ICHOM is committed to facilitating broad adoption of this set and has made the full recommendations freely available on its website [www.ichom.org/medical-conditions/inflammatory-bowel-disease], along with a reference guide to assist with technical aspects of implementation. The near-term goal will be to implement the set and to use this as a proof of concept towards broader adoption or endorsement by payors and governments. A steering committee will oversee revisions to the Standard Set to reflect changes in data collection capacity, to clarify outcome or baseline characteristics definitions as needed and respond to improvements in outcome measurement tools. In this way, the international IBD community can move towards the ultimate goal of acquiring internationally comparable data on patient-centred outcomes and improve the value of care.
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